Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Italy Singleplex Immunoassay Market

ID: MRFR/HC/54379-HCR
200 Pages
Nidhi Mandole
Last Updated: February 06, 2026

Italy Singleplex Immunoassay Market Research Report By Product and Service (Consumables, Instruments, Others), By Type (Protein-Based Assays, Nucleic Acid Based Assays, Cell-Based Assays, Others), By Technology (Flow Cytometry, Fluorescence Detection), By Application (Research & Development, Drug Discovery & Development, Biomarker Discovery & Validation, Clinical Diagnostics, Infectious Diseases, Cancer, Cardiovascular Diseases, Autoimmune Diseases, Nervous System Disorders, Metabolism & Endocrinology Disorders, Others) andBy End-user (Pharmaceutical & Biotechnology Companies, Hospitals and Research Institutes, Reference Laboratories, Others) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Italy Singleplex Immunoassay Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Pharmaceutical, BY Product and Service (USD Million)
      1. 4.1.1 Consumables
      2. 4.1.2 Instruments
      3. 4.1.3 Others
    2. 4.2 Pharmaceutical, BY Type (USD Million)
      1. 4.2.1 Protein-Based Assays
      2. 4.2.2 Nucleic Acid Based Assays
      3. 4.2.3 Cell-Based Assays
      4. 4.2.4 Others
    3. 4.3 Pharmaceutical, BY Technology (USD Million)
      1. 4.3.1 Flow Cytometry
      2. 4.3.2 Fluorescence Detection
      3. 4.3.3 Others
    4. 4.4 Pharmaceutical, BY Application (USD Million)
      1. 4.4.1 Research & Development
      2. 4.4.2 Clinical Diagnostics
      3. 4.4.3 Others
    5. 4.5 Pharmaceutical, BY End-user (USD Million)
      1. 4.5.1 Pharmaceutical & Biotechnology Companies
      2. 4.5.2 Hospitals & Research Institutes
      3. 4.5.3 Reference Laboratories
      4. 4.5.4 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Thermo Fisher Scientific (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Abbott Laboratories (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Roche Diagnostics (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Siemens Healthineers (DE)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Merck KGaA (DE)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Bio-Rad Laboratories (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Ortho Clinical Diagnostics (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 PerkinElmer (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 ITALY MARKET ANALYSIS BY PRODUCT AND SERVICE
    3. 6.3 ITALY MARKET ANALYSIS BY TYPE
    4. 6.4 ITALY MARKET ANALYSIS BY TECHNOLOGY
    5. 6.5 ITALY MARKET ANALYSIS BY APPLICATION
    6. 6.6 ITALY MARKET ANALYSIS BY END-USER
    7. 6.7 KEY BUYING CRITERIA OF PHARMACEUTICAL
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF PHARMACEUTICAL
    10. 6.10 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
    12. 6.12 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
    13. 6.13 PHARMACEUTICAL, BY PRODUCT AND SERVICE, 2024 (% SHARE)
    14. 6.14 PHARMACEUTICAL, BY PRODUCT AND SERVICE, 2024 TO 2035 (USD Million)
    15. 6.15 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
    16. 6.16 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
    17. 6.17 PHARMACEUTICAL, BY TECHNOLOGY, 2024 (% SHARE)
    18. 6.18 PHARMACEUTICAL, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
    19. 6.19 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
    20. 6.20 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
    21. 6.21 PHARMACEUTICAL, BY END-USER, 2024 (% SHARE)
    22. 6.22 PHARMACEUTICAL, BY END-USER, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY PRODUCT AND SERVICE, 2025-2035 (USD Million)
      2. 7.2.2 BY TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY TECHNOLOGY, 2025-2035 (USD Million)
      4. 7.2.4 BY APPLICATION, 2025-2035 (USD Million)
      5. 7.2.5 BY END-USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Italy Pharmaceutical Market Segmentation

Pharmaceutical By Product and Service (USD Million, 2025-2035)

  • Consumables
  • Instruments
  • Others

Pharmaceutical By Type (USD Million, 2025-2035)

  • Protein-Based Assays
  • Nucleic Acid Based Assays
  • Cell-Based Assays
  • Others

Pharmaceutical By Technology (USD Million, 2025-2035)

  • Flow Cytometry
  • Fluorescence Detection
  • Others

Pharmaceutical By Application (USD Million, 2025-2035)

  • Research & Development
  • Clinical Diagnostics
  • Others

Pharmaceutical By End-user (USD Million, 2025-2035)

  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Research Institutes
  • Reference Laboratories
  • Others

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions